Table 3—

Screening levels and changes from screening in NSC scores, NIS, and NIS[LL] after 5 weeks of treatment (last value carried forward)

PlaceboALA600ALA1200ALA1800
NSC number
    Screening6.8 ± 1.77.0 ± 1.67.1 ± 1.56.6 ± 1.5
    Change−1.7 ± 2.1−2.8 ± 2.1*−2.8 ± 2.2*−2.7 ± 2.5
NSC severity
    Screening14.1 ± 4.314.4 ± 4.414.7 ± 4.513.5 ± 3.5
    Change−4.9 ± 4.3−7.4 ± 4.6*−7.2 ± 5.0*−7.6 ± 4.2*
NSC change
    Screening−0.1 ± 0.70.0 ± 0.3−0.2 ± 0.60.0 ± 0.3
    Change+5.4 ± 4.6+8.6 ± 5.6*+8.5 ± 5.3*+9.5 ± 5.1*
NIS
    Screening19.2 ± 17.119.4 ± 17.618.7 ± 14.117.6 ± 15.8
    Change−2.38 ± 6.06−3.80 ± 4.61−3.85 ± 4.57*−3.85 ± 6.49
NIS[LL]
    Screening14.5 ± 14.615.4 ± 14.415.0 ± 11.113.0 ± 11.6
    Change−2.08 ± 5.57−3.75 ± 4.41§−2.63 ± 3.28−2.70 ± 5.33
NIS[LL] sensory function
    Screening7.05 ± 3.216.80 ± 3.767.21 ± 2.826.53 ± 2.79
    Change−1.05 ± 1.99−2.25 ± 2.27*−1.73 ± 1.72−1.55 ± 1.81
  • Data are means ± SD. Negative values correspond to improvement.

  • *

    * P < 0.05,

  • P = 0.08,

  • P = 0.055,

  • §

    § P = 0.07, and

  • P = 0.09 (each vs. placebo).